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Survival time doubled in
experimental studies

Liposomal muramyl tripeptide kills
bone cancer cells by stimulating the
immune system
Lab to Clinic
I

Eugenie Kleinerman is a
professor of cell biology
and pediatrics in the
Department of Cell
Biology

Until Eugenie Kleinerman, M.D., professor of
cell biology and pediatrics at The University of
Texas M. D. Anderson Cancer Center, began
treating bone cancer patients with liposomal
muramyl tripeptide (MTP), the choice of therapies for relapsed bone cancer was limited. The
disease, which is most common among teenagers, can be treated with chemotherapy, but it
quickly spreads to the lungs. If the lung metastases are refractory to chemotherapy, they usually
kill the patients in less than five months. Liposomal MTP treatment, however, has more than
doubled survival time, is well tolerated by patients, and can often be administered by private
physicians outside of cancer centers.
The new therapy is the cumulation of more
than 10 years of research at M. D. Anderson
Cancer Center. Kleinerman credits Isaiah Fidler,
DV.M., chairman of cell biology at M. D. Anderson, with sparking her interest in liposomal MTP
in 1982. "I heard him give a lecture at the annual
meeting of the American Association for Cancer
Research about his mouse model using liposomal
MTP, and it was like a light bulb went on, and I
said, 'That would work for osteosarcoma.' At the
time I was a fellow at the National Cancer Institute. Being a pediatrician, I was interested in
pediatric cancers, and one of the problems with
bone cancer is that it metastasizes to the lung.
Fidler had injected mice intravenously with MTP
and gotten uptake in the lung. It struck me that
if we could get MTP delivery to the lung we
could turn on the pulmonary macrophages and
eradicate the remaining tumor cells." (See box,
"How liposomal MTP works.")

Despite her excitement, Kleinerman already
had a research project, and it was difficult for her
as a junior faculty member to initiate another,
more speculative project. Some of her peers were
not enthusiastic about her idea, either. At the
time, biologically based therapies were uncommon, and osteosarcoma was not as high a priority
as lung or breast cancer. "It took me about a
month to get up enough nerve to speak to Fidler
about my idea," she said. But Fidler encouraged
Kleinerman's interest in treating osteosarcoma
patients with MTP. They began a collaborative
study, and eventually Kleinerman came to M. D.
Anderson. "The pediatric department here was
very receptive to my ideas and very receptive to
my having a joint appointment in cell biology,
treating patients, and moving my bench findings
into the clinic," she said.
So far, Kleinerman and her colleagues have
treated about 50 patients with liposomal MTP
·for pulmonary metastases refractory to chemotherapy. The first 16 patients were infused with
liposomal MTP for one hour twice weekly for 12
weeks and then once a week for another 12
weeks. These patients have lived twice as long as
untreated patients. Some are alive three years
after treatment, including one former pediatric
osteosarcoma patient who is now nearly through
college.
In addition to being effective, the treatment
was easy to administer and so relatively inexpen sive. The patients did not have to travel to a
cancer center to be treated-they could receive
continued on page 2
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MTP in an outpatient clinic or even in their
family doctor's office. Kleinerman explained, "It
took about half a day to train someone to administer the drug. And we had absolutely no problems, whether it was at a cancer center, the home
oncologist's office, or a general practitioner's
office." And MTP was well tolerated by the patients. "Patients generally liked the therapy. Some
asked to be on the regimen longer," said
Kleinerman. The few side effects, which included
fever, chills, and muscle aches, generally lasted
less than a day after administration and did not
prevent the patients from working or attending
school.
The encouraging results from Kleinerman' s
initial study have led to a unique national trial
combining liposomal MTP and chemotherapy to
treat newly diagnosed osteosarcoma. Two large
cooperative groups, the Children's Cancer Study
Group ( CCG) and the Pediatric Oncology Group
(POG), will collaborate in treating 500 patients
across the country. "It is very unusual for the two
groups to get together to do a study, but both are
excited about the potential of this agent, and so

they agreed to combine resources. By collaborating, we'll get the study done much faster," said
Kleinerman. Some patients will be treated at M. D.
Anderson, which will be the only institution in
the country to thoroughly study the patients'
immune systems, to better characterize how MTP
kills cancer cells. "I strongly encourage physicians in CCG and POG who have patients with
osteosarcoma to put them on the protocol," said
Kleinerman. Because the protocol combines chemotherapy and liposomal MTP administration,
patients will be treated at can cer centers, but the
possibility of outpatient treatment still exists. "If
the doctors feel comfortable giving chemotherapy,
I think they can certainly be trained to give MTP.
If they are not part of CCG or POG, and they
want to refer patients to M. D. Anderson, we
would be extremely grateful. We have worked
very hard to keep referring physicians involved
and up-to-date on what is happening. Some have
even written scientific papers with us."
The MTP trial will take three to five years, but
continued on page 5

How liposomal MTP works

M

TP induces a patient's own immune system to kill tumors. The drug is a syn th etic analog of a molecule contained in a mycobacterium. This molecule, w hich is the
smallest part of the mycobacterium to produce an immune response in patients, was
selected because of its effect on macrophages, the specialized immune cells that rid the
body of foreign objects. If MTP is taken up by macrophages, it transforms them into killer
cells that specifically destroy tumor cells.
But in its unmodified form, MTP is degraded by the kidney in about one hour, before
it can be taken up by the macrophages. In 1982, Isaiah Fidler, D.V.M., chairman of cell
biology at M. D. Anderson, first demonstrated that MTP administered to mice in liposomes
(small hollow spheres of lipid bilayers much like the membrane of a cell) is active long
enough to produce killer cells. In the macrophages, MTP is gradually released from the
liposomes ("like a time capsule," said Kleinerman) and is active for about eight hours.
The body's rapid and selective response to liposomal MTP targets the drug to the liver,
spleen, and lungs, but it prevents the drug from reaching other organs. Demitrios
Papahadjopoulous of the University of California at San Francisco and Theresa M . Allen of
the University of Alberta have changed the composition of standard liposomes to develop
Stealth™ liposomes-chemically altered liposomes that better avoid degradation and so
stimulate killer-cell production longer. Such improvements in liposome technology may
not only make MTP treatment of osteosarcoma more effective-they may also enable MTP
to reach other organs and thus be effective against other kinds of cancer. An oral
preparation of MTP, which would be even easier to administer than liposomal MTP, is also
being developed.
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Garlic may contain compounds that
prevent esophageal and colon tumors

Researcher studies the
hemopreventive power of garlic
"O ur apothecary's shop is our garden full of
pot-herbs, and our doctor is a clove of garlic," an
anonymous author wrote in 1615. Modern science tends to dismiss such folk remedies as superstition , but in the case of garlic, this Renaissance
writer's beliefs may have a solid scientific foundation . Recent studies have suggested that garlic
migh~ be helpful in curing various skin diseases,
in lowering blood pressure, and in inhibiting
platelet aggregation, possibly reducing the risk of
heart attack. To the centuries-old lore of the
power of garlic as an antibiotic, Michael J.
Wargovich, Ph.D., associate professor of medicine at M. D. Anderson Cancer Center, has added
data showing garlic's effectiveness in preventing
the development of esophageal and colon cancer
in rodents. Other laboratories have shown garlic
to be active against mammary cancer, skin cancer,
and lung cancer in rats.
Because of these results in animals, and because it is a natural, edible substance, garlic is
promising for cancer prevention in humans, said
Wargovich, whose laboratory is one of the
National Cancer Institute's primary screening
laboratories for potential colon cancer chemopreventives. The search for compounds that prevent cancer has intensified with the mounting
evidence that many types of cancer are caused or
triggered by factors relating to lifestyle and environment. One of two basic scientists who work
alongside clinicians in the Department of Gastrointestinal Medical Oncology and Digestive Diseases, Wargovich is working on several projects
with the hope of showing that chemopreventive
agents are available on a grocery shelf.
Garlic extract prevents esophageal and colon
tumors in rodents
Wargovich encountered garlic's chemopreventive properties almost 10 years ago, during a
postdoctoral fellowship at the Ludwig Institute
in Toronto, where he developed an assay system
for determining whether various compounds could
suppress the DNA-damaging effects of carcinogenic agents. When researchers at New York

University later found that garlic and onion oils
inhibited tumor formation in a skin carcinogenesis assay, W argovich tried the garlic oil in his
system and was intrigued to find minor suppression of damage to mouse nuclei.
He set out to discover which of the 60 to 100
chemicals in garlic had led to the inhibition and
found that most of the preliminary work had
already been done. Since garlic has been used for
centuries as a flavoring agent, the food industry
already had isolated 20 to 40 of its chemical
components. Wargovich's laboratory bought
samples of 13 of them and began systematically
testing them in the colon carcinogen assay.
"Right away, we came up with an extremely
active substance that to this day is one of the most
powerful anticarcinogens around," Wargovich
said. The compound was diallyl sulfide (DAS),
"notorious for its odor," he said; "it smells pretty
awful in the laboratory." Wargovich demonstrated
that DAS inhibits the formation of 1,2-dimethylhydrazine (DMH)-induced colon tumors in mice.
He continued his experiments after coming to
M. D. Anderson in 1984 and found that the
amount of tumor inhibition correlates linearly
with the dose of DAS administered. "I began
thinking that DAS might be helpful in other sites
along the digestive tract," Wargovich said. He
undertook a study of nitrosomethylbenzylamine
(NMBA)-induced esophageal tumors in the rat
and found that DAS completely inhibited the
tumors from developing.
Will these results in mice and rats translate into
prevention of cancers in man? Wargovich is optimistic. He noted that the types of tumors induced by DMH and NMBAin rodents are similar
to colon tumors and squamous cell esophageal
cancers seen in humans. However, several challenges remain in developing DAS for use by man,
he said. First, little is known about DAS's distribution around the body. Second, because ofDAS's
distinctive odor and taste, it would be difficult to
do a blind clinical trial; however, one solution to

Cancer Prevention

Michael J. Wargovich is an
associate professor of
medicine in the Department of Gastrointestinal
Medical Oncology and
Digestive Diseases

continued on page 4
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"Sure, eat more garlic, but don't
go overboard, because it can
have toxic effects"
•
that problem would be to give control subjects
lower, noneffective doses of the compound.
A third drawback of DAS is that because it is
lipid soluble, it breaks down when heated., "If
you smell garlic cooking in your kitchen, you've
destroyed a lot of the compounds that we think
are cancer preventive," Wargovich said. Because
people are hesitant to eat a lot of raw garlic, his
laboratory is investigating some ofits water-soluble
components, which persist during limited heating and are far less smelly. "We're trying to find
a potential chemopreventive agent that's palatable," he said. One water-soluble compound that
he has found effective in inhibiting DMH-induced
colon tumors in mice is S-allyl-cysteine (SAC).
Although larger doses of SAC than of DAS are
required for inhibition, SAC seems to be less
toxic.
Garlic targets enzyme systems in the liver
The key to garlic's effectiveness in these experiments may not lie in its direct effects on the
colon and esophagus, but rather in preliminary
biochemical reactions in the liver. Evidence suggests that garlic affects two liver enzyme systems
that could be responsible for the anticarcinogenic
effects, Wargovich said. The first involves a form
of cytochrome P450 that, in metabolizing DMH
and NMBA, activates these carcinogens. DAS has
been shown to inhibit this enzyme system. The
second enzyme system involves the liver's detoxification pathway. Wargovich has shown that DAS
boosts the activity of glutathione S-transferase,
which joins foreign substances (such as DMH
and NMBA) with glutathione, forming complexes
that are excreted from the liver in bile.
Last year, Wargovich and his colleagues found
that carcinogenesis in the rat esophagus is inhibited if DAS is administered before, but not after,
NMBA. This result further supported the idea
that DAS modifies the metabolic activation of
NMBA or increases detoxification activity. In this
study, Wargovich also noted that DAS does not
itself promote the production of esophageal tumors. This observation was encouraging because
a number of promising agents that block the early
phases of carcinogenesis in one organ have been
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found after chronic testing to promote tumorigenesis in another organ and thus cannot be used
in man.
Most data suggest that the detoxification pathway is responsible for the preventive effects
Wargovich has observed, he said. "That's good in
that we are exposed daily through breathing and
food to an array of environmental carcinogens,"
he said. However, if garlic increases the detoxification activity in the liver, other medications and
analgesics are probably excreted along with the
carcinogens. The liver doesn't recognize the difference between a drug and a poison; both types
of chemicals are treated the same way, Wargovich
said.
Wargovich has been collaborating on this research with Wakunaga Pharmaceutical Company,
which sells over-the-counter garlic preparations
in Japan. Whereas Asians have been using garlic
medicinally for centuries, Wargovich noted, "in
this country, we 're a little behind in using foods
and herbs for medication."
Wargovich and W akunaga researchers have
proposed the first clinical trial of these garlic
derivatives. Since they are beginning to understand how DAS and SAC wo rk, they plan to
target people who would benefit most from
them-those who are exposed to high levels of
carcinogens in their lifestyle. Levels of glutathione S-transferase are lower in Japanese smokers
than in nonsmokers; the trial would reveal whether
garlic compounds can boost the levels of this
enzyme in smokers, thereby restoring the protective detoxifying function of the liver. Successful
results from this and other trials could lead to
new chemoprevention regimens for people at
high risk of developing cancer.
Anticarcinogenic "designer foods" are a possibility
Wargovich is often asked whether his results
mean people should start eating lots of garlic.
"My answer is, sure, eat more garlic," he said.
"But don't go overboard, because it can have
toxic effects." Since garlic is a good antibiotic,
too much can wreak havoc on the gastrointestinal
system. Wargovich also noted that researchers
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haven't pinpointed a single food that will prevent
cancer. "It is likely that a mixed diet with a lot of
different chemopreventive agents (e.g., fresh fruits
and vegetables) will be most effective," he said.
( Other potential chemopreventive compounds
Wargovich is studying are aspirin and calcium.)
Only limited experimentation has been done with
combinations of chemopreventive agents (e.g.,
garlic and citrus fruits), but in almost every case,
he said, the combination has been more effective
in inhibiting carcinogenesis than has any single
agent.
A project that Wargovich is working on with
Dr. Leonard Pike, head of the Vegetable Improvement Center at Texas A&M, aims to create
a "designer food " that is enriched in chemopreventive agents and is palatable. This idea combines 1990s technology with an old approach.
"The major diseases in this country were conquered by supplementation-putting vitamins in
bread, iodine in salt," Wargovich noted. However, one question that is raised by such supple-

mentation is where the Food and Drug Administration draws the line between a food ·and a
drug.
Pike spent 10 years breeding the sulfur compounds out of onions, resulting in the Texas
1015 supersweet onion, which has been very
popular. Using traditional breeding methods, just
as the 19th-century botanist Gregor Mendel did,
Pike will try to develop a garlicky-tasting onion
that is rich in the chemopreventive agents
Wargovich has been studying. "Plant geneticists
have long bred crops for color, size, and marketability," Wargovich said. "Now they are breeding
crops for health benefits." ■

MTP

combining interleukin-I with a common chemotherapeutic agent, VP16 [etoposide]. We found
in the laboratory that cells that are resistant to
VP16 can be made sensitive if you combine interleukin-I with VP16," she explained. As in her
MTP study, she is carefully considering the most
effective way to use the drug, to maximize its
biological effect while minimizing the cost and
the disruption to patients' lives. "I think this is
the way we 're going to have to go in cancer
treatment-managed care. We're going to have
to start looking for therapies that are more cost
effective, that don't take people away from home,
so that they can continue working and going to
school," she emphasized. ■
-MAUREEN E. GOODE

continued from page 2
because the disease-free survival time for untreated patients is so short, Kleinerman anticipates that the success or failure of the treatment
can be estimated in a year or two. If liposomal
MTP is effective against primary osteosarcoma, it
may be administered with other therapies or for
longer periods of time than in the initial study.
Liposomal MTP may also be used to treat
other cancers. Because her laboratory studies
showed that liposomal MTP is taken up by the
liver, spleen, and lungs, Kleinerman believes that
liposomal MTP may be effective against other
cancers that affect these organs, including colon
cancer, which frequently metastasizes to the liver.
A small pilot study of20 patients at M. D. Anderson also showed that liposomal MTP is successful
in treating melanoma. Unfortunately, there is a
limited amount of liposomal MTP available, and
it is being reserved for those patients who participate in the national osteosarcoma trial. For
osteosarcoma patients who cannot be treated with
MTP or are not cured by it, Kleinerman is exploring another biologically based therapy. "We're

-SUNITA PATTERSON

Physicians who desire additional information may
write Dr. Wargovich, Department of Gastrointestinal
Medical Oncology and Digestive Diseases, Box 78,
The University ofTexas M. D. Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, Texas
77030, or call (713) 792-7493.

Physicians who desire additional information may
write Dr. Kleinerman, Department of Cell Biology,
Box 173, The University of Texas M. D. Anderson
Cancer Center, 1515 Holcombe Blvd., Houston, TX
77030, or call (713) 792-8110.
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'-Our patients come to us now
asking for the gene therapy they've
heard about on television~
•

Gene Therapy
continued from page 8

Jack Roth is chairman of
the Department of
Cardiovascular and
Thoracic Surgery

Sewa Legha is chief of the
Melanoma Section of the
Department of Medical
Oncology

tors using these approaches experimentally to
treat melanoma are looking for an alternative to
conventional immunotherapeutic treatment,
which, although effective in some patients, is
extremely toxic. They hope that the new therapies will allow local, rather than systemic, administration of larger and more effective doses of the
standard chemotherapy or radiotherapy without
the often intolerable side effects of those therapies.
Chemoprotection: a second approach
These are also the hopes of a team of scientists
at M . D. Anderson who are investigating a second gene therapy approach called "chemoprotection." The team, led by Albert B. Deisseroth,
M.D., Ph.D., Chairman of the Department of
Hematology, is investigating the application of
gene therapy in protecting normal cells and tissues from the often ravaging effects of chemotherapy and radiotherapy. As Deisseroth pointed
out, "Over the past 50 years, the limiting factor
in our ability to effectively treat patients with
solid tumors has been the damage that the treatment causes to normal cells. The goal of chemoprotection is to save lives by allowing patients to
benefit more from these standard treatments."
A third approach "corrects" genetic defects
Jack A. Roth, M.D., Chairman of the Department of Thoracic and Cardiovascular Surgery at
M. D. Anderson, has taken a third and very different approach by attempting to correct the
genetic defects that cause the cancer. This approach, called "replacement," comprises two different strategies. In one, the objective is to correct
a mutation that prompts a proto-oncogene, a
gene that controls cell growth and division, to go
awry and become an oncogene, a gene that allows the uncontrolled cell proliferation that leads
to the development of tumors. Roth's team uses
a complementary "antisense," or mirror-image,
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strand of RNA that incapacitates the cancer-causing oncogene by forming a duplex with it. The
second strategy is to replace defective tumor suppressor genes, genes that would otherwise block
the effects of oncogenes, with functioning ones
by administering them directly to the tumor cells.
Both chemoprotection and replacement have
been successfully applied in laboratory experiments. The chemoprotection approach has undergone extensive testing in human ovarian cancer
cell cultures and in cancerous mice at the N ational Institutes of Health (NIH). Likewise, in
work done at M. D. Anderson by Roth's team ,
replacement strategies have been shown to work
in lung cancer cell cultures and in mice in which
lung tumors had been induced. The NIH Re combinant DNA Advisory Committee, which
must approve all U.S. human gene therapy protocols, recently gave both teams the go-ahead to
try these therapies as phase I ( dose and toxicity)
studies in human cancer patients in whom other
therapies were ineffective. The chemoprotection
team's first clinical trial, scheduled to begin this
winter, will take normal bone marrow cells from
patients with advanced ovarian tumors. The cells
will be altered with a gene that will help them
resist the damaging effects of paclitaxel (Taxol® ),
an agent known to be effective against ovarian
tumors at an intolerably high dose. After the
altered cells are returned to the patients, the
patients will receive progressively higher doses of
paclitaxel, which Deisseroth hopes will destroy
their tumors while leaving their bone marrow
unharmed. Bone marrow cells were chosen for
the treatment because they are the most sensitive
in the body to the toxic effects of chemotherapy.
Roth's team's study will encompass both replace ment strategies in lung cancer patients.
Therapies still highly experimental
Both investigators cautioned, however, that
these therapies are still in extremely early experimental stages, that they are being used only on a
few patients, and that the outcomes are uncertain. Although hopes are high, of course, Roth
said it is too early to talk of "cures." For example,
the technology that allows delivery of foreign
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"The goal of chemoprotection
is to save lives by allowing
patients to benefit more from
these standard treatments~
•
genes into living human cells has not yet been
perfected. Therapeutic genes are usually delivered through recombinant retroviruses that are
designed to "infect" cells, get into the nuclear
DNA, and insert the gene into the genome ( the
individual's complete genetic material) so that it
can perform its intended function. He is quick to
mention that the retroviruses have been "safety
modified" to not cause disease.
Integrational mutagenesis a theoretical possi-

bility
Although the outcomes in animal studies suggest that the incorporation of the foreign gene
into the cell's DNA has no effect on the host
other than the desired one, there is as yet no way
to ascertain this specificity. Deisseroth admitted
that there is a theoretical possibility of "integrational mutagenesis," in which the introduced gene
pos1t10 ns itse lf improperly and causes
dysregulation in the cell's function, which may
develop into a second tumor. He discounted the
possibility as being much less likely than a second
tumor or a fatal toxic reaction in a patient receiving a standard therapeutic modality. Although he
agreed that the outcomes of human gene therapy
are unknown, he believ~s that its use poses no
ethical dilem ma. He pointed out that the
prognosis of patients who are to receive these
experimental therapies is poor and that the chemoprotection protocol is a next logical step, given
the efficacy of the available treatments.
Sewa Legha, M.D., chief of the Melanoma
Section in the Department of Medical Oncology,
is head of M. D. Anderson's Institutional Review
Board ( IRB), which is responsible for reviewing,
on behalf of the institution, the scientific merit,
ethics, safety, and other aspects of clinical protocols implemented at M. D. Anderson. He emphasized that these therapies, because they do
not tamper with reproductive cells, do not result
in the "genetically altered" humans that some
critics fear will result from gene therapy. Legha
said that most scientists working in the field of
genetics now believe that the fears of genetic
manipulation that arose 20 years ago when the
recombinant DNA technology was new do not

apply to modern gene therapy, which affects only
the patient treated, not his offspring; the effects
last only as long as the patient lives.
Although he is enthusiastic about the possibilities for gene therapy in his own area of clinical
expertise, Legha agreed that the day when we can
offer gene therapy cures is still far off. He cited
the extensive work that must be done and the
problems that must be overcome before gene
therapy can become reality. First, the genetic
abnormality must be identified. This is part of the
purpose of the international Human Genome
Project, which by "mapping" the normal human
genome will provide a baseline with which to
compare genetic abnormalities. Only when the
genetic abnormality responsible for a disease is
identified can a specific gene therapy be developed.
For now, best hope for most patients is standard therapy
Legha said, "Our patients come to us now
asking for the gene therapy they've heard about
on television. Naturally enough, they don't want
the standard therapies, which may have undesirable side effects, but the gene therapy that they
believe will cure them. We explain that the gene
therapy is entirely experimental and that they are
not eligible for the protocol. We tell them we
have treatments that are tested and more effective, but gene therapy, with its potential for cure,
is so intuitively attractive that sometimes they
don't want to listen. For now, however, their best
bet is to start with the standard therapies or the
more widely accepted experimental therapies."
-KATHRYN L. HALE
Physicians who desire additional information may
write Drs. Roth, Deisseroth, or Legha at the Departments ofThoracic and Cardiovascular Surgery (Roth),
Hematology (Deisseroth), or Medical Oncology
(Legha), The University of Texas M. D. Anderson
Cancer Center, 1515 Holcombe Blvd., Houston, Texas
77030, or call (713) 792-6932 (Roth), 792-8750
(Deisseroth), or 792-2921 (Legha).
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Therapies still experimental, caution researchers

Gene therapy at M. D. Anderson
Lab to Clinic

Albert Deisseroth is
chairman of the
Department of
Hematology

Gene therapy. You may ha e heard about it on
the television or radio, seen it in the newspapers.
It's being compared to vaccines and antibiotics as
the next great discovery in medicine. You may
~ven have had patients ask about it, for themselves or for a family member. What does gene
therapy mean, and what are its implications for
curing diseases and caring for patients?
The term "gene therapy" encompasses a number of different therapeutic strategies, but all
involve the introduction of an exogenous gene to
stimulate a desired response in the body. The
diseases it targets have only two things in common: they are all serious, and they are all caused,
at least in part, by a defective, mutated, or missing human gene that disables the body's natural
protection against disease. The obvious targets
are hereditary diseases, notably cystic fibrosis,
various enzyme deficiencies, and hemophilia, but
gene therapies are also being tried in immunodeficiency diseases, heart disease, and neurological
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Gene therapies for cancer \: ork in one of thr e
fundamental wa s. One approach \J ork with the
body's natural immune s tern to enhanc the
body's ability to fight the growing cancer. The
therap may, for example stimulate the immune
system to produce large quantitie of endogenous cancer-killing substances or alter the cancer cells so that the immune s stem can more
efficiently recognize and attack them. In estigacontinued on page 6

